Literature DB >> 9858147

Thrombopoietin serum concentration in patients with reactive and myeloproliferative thrombocytosis.

M Uppenkamp1, E Makarova, S Petrasch, G Brittinger.   

Abstract

We wished to test whether thrombopoietin (TPO) is entirely regulated by receptor binding or if other factors may play a role in the mechanism of TPO regulation. Therefore, we analyzed the TPO serum levels in 43 patients with reactive (secondary) thrombocytosis and in 37 with myeloproliferative thrombocytosis. Thrombocytosis was defined as a platelet level greater than 440 x 10(9)/l. Forty-two patients (98%) with reactive thrombocytosis had high concentrations of IL-6 correlating with elevated C-reactive protein levels. Twenty-three patients (53%) in this group had TPO serum concentrations of more than 300 pg/ml (normal: below 300 pg/ml). Only nine patients (24%) with myeloproliferative thrombocytosis had TPO serum levels above normal range, whereas 28 patients (76%) had normal levels of TPO. No correlation between the TPO serum levels and the concentrations of IL-6 or EPO was established. The other investigated thrombopoietic cytokines (IL-3, IL-11, GM-CSF) were unmeasurable; therefore, a correlation could not be assessed. We conclude that TPO concentrations are not strictly inversely related to platelet count. TPO serum levels are elevated especially in a considerable percentage of patients with reactive thrombocytosis, arguing for the existence of additional mechanisms of TPO regulation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9858147     DOI: 10.1007/s002770050446

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  6 in total

1.  Mpl expression on megakaryocytes and platelets is dispensable for thrombopoiesis but essential to prevent myeloproliferation.

Authors:  Ashley P Ng; Maria Kauppi; Donald Metcalf; Craig D Hyland; Emma C Josefsson; Marion Lebois; Jian-Guo Zhang; Tracey M Baldwin; Ladina Di Rago; Douglas J Hilton; Warren S Alexander
Journal:  Proc Natl Acad Sci U S A       Date:  2014-04-07       Impact factor: 11.205

2.  Erythropoietin-induced neuroprotection requires cystine glutamate exchanger activity.

Authors:  Brian Sims; Melinda Clarke; Wilfred Njah; E'lana Shuford Hopkins; Harald Sontheimer
Journal:  Brain Res       Date:  2010-01-25       Impact factor: 3.252

3.  Thrombocytosis: diagnostic evaluation, thrombotic risk stratification, and risk-based management strategies.

Authors:  Jonathan S Bleeker; William J Hogan
Journal:  Thrombosis       Date:  2011-06-08

4.  Characterization of ENU-induced Mutations in Red Blood Cell Structural Proteins.

Authors:  Katrina Kildey; Robert L Flower; Thu V Tran; Robert Tunningley; Jonathan Harris; Melinda M Dean
Journal:  Comput Struct Biotechnol J       Date:  2013-09-23       Impact factor: 7.271

Review 5.  Platelets and cancer angiogenesis nexus.

Authors:  Marek Z Wojtukiewicz; Ewa Sierko; Dominika Hempel; Stephanie C Tucker; Kenneth V Honn
Journal:  Cancer Metastasis Rev       Date:  2017-06       Impact factor: 9.264

6.  TPO, but not soluble-IL-6 receptor, levels increase after anagrelide treatment of thrombocythemia in chronic myeloproliferative disorders.

Authors:  Jan Palmblad; Magnus Björkholm; Jack Kutti; Gerd Lärfars; Eva Löfvenberg; Berit Markevärn; Mats Merup; Nils Mauritzson; Jan Westin; Jan Samuelsson; Gunnar Birgegård
Journal:  Int J Med Sci       Date:  2008-04-13       Impact factor: 3.738

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.